International Journal of Advances in Pharmacy Medicine and Bioallied Sciences. 2022;10(2):59-66.

International Journal of Advances in Pharmacy Medicine and Bioallied Sciences
An International, Indexed, Peer-reviewed Open Access Journal
www.biomedjournal.com

ISSN 2348-2109
International Journal of Advances in Pharmacy Medicine and Bioallied Sciences
www.biomedjournal.com
Indexed Peer-reviewed

Review Article

Immunology and immunotherapy of pulmonary adenocarcinoma: a systematic review.

Rupali Jaiswal, Priti Verma, OP Verma, Amresh Gupta, Deepti Upadhyay*.

Goel Institute of Pharmacy and Sciences, Faizabad Road, Lucknow, Uttar Pradesh, India.

ARTICLE INFO

Article History

Received : 17-Jun-2022
Revised : 19-Jun-2022
Accepted : 22-Jun-2022

Key words

Immunotherapy,
Immune cells,
Lung cancer,
Prognosis.

ABSTRACT

Lung cancer is the world's second leading cause of death, with an estimated 9.6 million deaths in 2018. Approximately 80% of all lung cancer is caused by non-small cell lung cancer (NSCLC). Due to a lack of early detection and treatment, the incidence rate of lung cancer prognosis remains low. CD4+T-lymphocytes, macrophages, dendritic cells, and natural killer cells are among the immune cells involved in the pathogenesis of lung cancer. The through immune cells suggest their participation in each stage of lung cancer to be highly complex and networked. Types and quantities of immune cells influence prognosis and may provide a possibility for medicinal therapeutic applications. Nevertheless, there is an insufficient view of the role of immune cells and the fundamental mechanisms of lung cancer. In recent year's cancer immunotherapy has revolutionized conventional cancer treatment, including cancer vaccination, genetic cancer therapy, and immune response point therapy. Types of immune cells affect prognosis and may offer clinical therapeutic applications an opportunity. Nevertheless, there is still an inadequate knowledge of the role of immune cells and the underlying mechanisms in lung cancer; difficulties remain in this field. More studies on the function of immune cells will improve knowledge of lung cancer and establish clinical strategies to diagnose and handle patients with more advanced and specific lung cancer.

*Author for Correspondence: deeptiupadhyaykni1996@gmail.com

DOI: https://doi.org/10.5281/zenodo.7045986

INTRODUCTION

Lung carcinogenesis commonly affects the system in the body the respiratory system. The highest causes of death worldwide, with an estimated 159,260 deaths in 2014 [1]. An overview of cancer distribution globally in 2002 found lung cancers to be the most commonly recognized cancer annually since 1985. Nevertheless, particular attention has been paid to the role of thoracic radiation therapy (TRT) in the past year. In the 1970s and 1980s, numerous research was carried out to check whether the addition of TRT to chemotherapy was really helpful in the treatment of limited-stage small-cell lung cancer (LS-SCLC) [2]. Morphologically, lung cancer has two types: small-scale lung cancer (SCLC) and non-small-scale lung cancer (NSCLC). NSCLC accounts for nearly 80% of all lung cancer manifestations and includes three histological subtypes: squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Around 80-90% of NSCLCs are directly linked to tobacco smoke. Though SCLC accounts for around 20% of lung cancers and almost all SCLCs are correlated with smoking [3].

The immune system inevitably performs a vital and multifaceted position in lung cancer as the natural protection of human physics against disease. The hypothesis of immune enhancement discusses immune involvement in volume control, the quality of



Figure 1. Nicotine and lung cancer-mechanism.

tumor development, immunosuppression, and immune cell tumor infiltration respectively [4].

Lung cancer is commonly found and that attention is given; nevertheless, lack of early analysis techniques and lack of clinical therapies are the main reasons why many patients still have a poor prognosis. Therefore, to increase new therapeutic techniques such as immunotherapy, there is a need to elucidate the immune mechanisms. However, the disorder's unique regulatory mechanisms are not well understood. Different work has shown that tumor-infiltrating lymphocytes, specifically CD4 + support T cells, are present in the lungs of patients with non-small cell lung cancer [5].

The goal of this paper is to review in a significant way the open literature on the cellular and molecular relationship between the immune system and lung cancer. In turn, emerging treatment modalities that stimulate the immune system in comparison to lung cancer are addressed. Particular emphasis is placed on immune cells and molecular signals in lung cancer. Where there is no evidence, however, statistics are drawn from parallel pathology research [5].

Lung carcinogenesis

The lung is a highly specialized and vital organ designed to optimize the flow of gases. It has a twofold distribution. The bronchial, and pulmonary drainage supports the lung tissue for respiratory needs. Deoxygenated blood is transmitted through the alveolar airspace interface through the pulmonary circulation. Each movement is precisely ordered and tightly regulated in the typical lung with few anastomoses between the two.

Several factors, along with genetic susceptibility and occupational or environmental cancer agents, play a causative role in the pathogenesis of lung cancer [6].

Exposure to a variety of factors, along with asbestos, other contaminants, radon, other natural substances, pre-existing lung disease, dietary preparation, and family history, are predisposing conditions for lung cancer participation. Many cases of lung cancer are triggered by tobacco smoke, smoking is no longer due to 25 percent of global cases of lung cancer. Striking differences have been identified in the epidemiological, medical, and molecular features of lung cancer in non-smokers and smokers. The principal signaling pathways of the pathogenesis of lung cancer consist of epidermal growth factor (EGF) mutation, translocation of anaplastic lymphoma kinase (ALK), and mutations of the family gene RAS (including KRAS, NRAS, HRAS). These cancer-causing agents act in severe approaches to promote oncogenesis [7].

Nicotine dependency is an effective mechanism that stops the quitting of people who smoke. Before both are secreted or can bind to DNA by adduct formation, the many lung-specific cancer agents in tobacco smoke particulate memories must be metabolized. DNA adducts can also be restored or apoptosis can be done. When they persist, miscoding mutations in main genes such as P53 or RAS may contribute to genetic instability, contributing mostly to severe mutational damage and ultimately cancer [8].

CD4+ T helper cells

CD4+T-lymphocytes play an important role in guiding the immune response, especially in tumor improvement and/or rejection. With regular T cells, specific types of CD4 T cells continue. When triggering the numerous cytokines, the naive CD4+cells are selected via several transcription elements in response to a variety of cytokines or different mediators. Like this phenotype, Th1 cells become polarized in response to IL-2 and IFN-α and the transcription factor



Figure 2- CD4+ T cells and its classification.

T-bet, now the destiny of these cells is controlled. These Th1 cells can produce numerous cytokines upon activation, triggering cell-mediated effector functions such as CTLs, NK, and macrophages. Then the cells of the effector kill all intracellular micro-organisms and virus-contaminated cells [9].

CD4+ T cells can presently be classified into at least four different kinds and each has its special function.
Fig. 2: Helper T cell 1 (Th1) and helper T cell 2 (Th2) are immune cell forms that modulate the different activities of the immune cell. Although the cell immune system Th2 it is recognized that Th1 is usually involved in the humoral immune system. Although Th2 reactions to allergens, the response of Th1 to microbes has been established. Ironically, Th1-induced molecules have been validated to suppress the allergen-specific response of Th2 and vice versa (Bellanti, 1998). Such shared regulation of Th1 and Th2 cells led some researchers to conclude that the absence of microbial load, which usually promotes high Th1-mediated immunity in established international locations, redirects the immune response to a Th2 phenotype and thus predisposes the host to allergic problems. The problem with this hypothesis is that Th1 cell-mediated autoimmune diseases have also been shown to be regulated by Th1-inducing infections and that Th2 triggering allergic reactions can be halted by parasites resulting in a Th2 reaction [10].

Th1 and Th2 cells in immune modulation

A key element in the daily immune system is the division of naive CD4 + T cells into subtypes with specific phenotypes [9]. The first important groups in the beginning studied are the Th1 and Th2 cells, exceptional, especially for cytokine manufacturing [10]. Th1 cells are distinguished by the development of pro-inflammatory cytokines IFN-π, TNF-α, and TNF-β, which cause two cytolytic immune reactions: endogenous and cell-mediated. Th2 cells produce IL-4,IL-5,IL-6,IL-9,IL-10,andIL-13. The answer from Th2 promotes two immune globulin classification switching, eosinophil recruitment, and, most notably, promotes the humoral immune response. Enhanced release of IL-4 and IL-5by Th2 cells promotes the development of IgE antibodies by the B cells. In turn, IgE is responsible for allergic reactions such as high fever. IgE functions as an effector in the fight against large extracellular parasites such as helminths. A common Th17/Treg cell is stimulated by TGF-β. IL-6, IL-23, TGF-β, IL-1β (in humans) and PGE stimulation [10].

TNF-α, some other primary Th1 cytokine, performs a role among a variety of different innate immune cells in the priming, proliferation, and recruiting of tumor-specific T cells. TNF-α knockout displayed signs and symptoms of early tumor growth and progression in a pancreatic mouse model, promoting TNF-α's critical

immune response and immune surveillance. As far as adaptive immunity is concerned, Th1 cells trigger predominantly and result in the proliferation of CD8 + cytotoxic T lymphocyte proliferation targeted mainly at cancer cells. It has been shown that mild infiltration of CD8+T cells and severe infiltration of CD4+T cells significantly increase the survival rate of NSCLC sufferers [11].

On the other hand, T-helper type 2 cells are no longer of high quality in tumor discharge. The cytokines developed by Th2 cells have pro-tumor and some immunosuppressive effects regularly. It has been shown that human NSCLC cells produce type 2 cytokines. Contributing to a pro-tumor micro-environment and indicating an NSCLC Th2 climate. IL-4, a cytokine Th2 receptor, stimulates and matures B cells and separates Th2 cells. In most tumors, IL-4 stimulates lung development and metastasis by stimulating cathepsin protease regeneration for tumor-associated macrophages (as well as pancreatic islet and mammary). Polymorphism IL-4-590T / C down-regulates the production of IL-4 and is correlated with decreased NSCLC susceptibility. IL-6 is also pro-tumorigenic in lung cancer through the help of STAT3 and NFkB pathways, which work together to facilitate prosurvival, antiapoptotic, and proangiogenic markers [11].

CD4 + cells historically play an indirect, but important, immune response role. In each infection and malignancy, CD4 + CTLs with cytotoxic capacity provide an especially clear role for CD4+cell-mediated immunity. A lytic recreation is assumed to be extraordinarily executed through the cytotoxic process, while numerous investigations indicate CD4 + CTL perforin, granzyme B, and granulysin secretion. We provide a possible avenue of cancer immunotherapy for the use of the host immune system [12].

Th 17 and Treg paradigm

However, Th17 cells tend to recruit myeloid cells like neutrophils, monocytes, and macrophages as their effector cells. Extracellular bacteria, viruses, and fungi are handled by these myeloid effector cells. Positive autoimmune diseases are regulated by overactive Th17 cells. The configuration of FoxP3 as a consequence of the transcription factor becomes the dominant transcription factor [13].

The Tregs can suppress the actions of Th1, Th2, and Th17 cells. In addition, Tregs are brakes configured to suppress an over-energy immune response in the direction of any given antigen. And Treg may be finished, producing immunological self-tolerance. Th17 and Tregs share a common path, each requiring early development of TGF-β. stimulates Th17 cells to evolve, and IL-23 encourages the development of Th17 cells that have already been formed. Tregs, on the other hand, uses IL-2 as an increase item and possesses the FoxP3 transcription factor. It influences the maturation and the function of the effector. To suppress these cells in Treg, Antibody IL-2R β receptor or recombinant protein IL-2-diphtheria toxin fusion [14]. Protein can be used to destroy these cells instantly and enhance immune responses to tumors. Cyclophosphamide kills Treg cells in addition to being an alkylating chemotherapeutic drug. Tregs hinder the process of the immune system by containing the TGF-β membrane. Tregs produce TGF-β soluble [15].

Most studies also reported that lung cancer can also occur as a consequence of cytokine dysfunction and the Th17/Treg ratio subsequently. For eg, TGF-β cancer of small cells and non-small cell lung cancer cells [16]. Serum concentrations of TGF-β have been elevated in the lung in most patients with lymph node metastasis relative to patients with lymph node metastasis, and the levels of TGF-β in patients with stage III illness were significantly higher than in patients with stage I and stage II. Activated TGF-β promotes metastasis of tumors. TGF-β has suppressive relaxation in early tumorigenesis, but in the later levels of the disease, it can also be tumor-promoting [17]. Since TGF-β synergizes with IL-6 and IL-21 in the early stages to facilitate separation with Th17, TGF-β in the late stages will need a Treg response. It is known that levels of Th17 and Treg cells are associate with NSCLC stage. Although there is some evidence of the detrimental prognostic effect of Treg cells. We have an impact on lung cancer Th17 cells and Th17/Treg cell ratios need to be established honestly [18].

Differentiation of Th1, Th17, and Tregs by generating a variety of cytokines had been driven by activation of APCs, which had previously been triggered by TLRs. Therefore, TNF promotes APC-derived Tregs and TGFb and further promotes Th17 with TGFb IL-1, IL-6, and IL-23. Use TLR agonists and autoimmunity to cause Th17 responses. In addition, APC induction produces IL-12 promoting IFN Y producing Th1 cells suppresses Th17 responses, and promotes Treg activity by TLR agonists. Hence, Th17, Th1, and Treg polarization due to TLR activation can try or battle autoimmunity. TLR activation can also play a dual function, either by suppressing immune responses relative to tumors or by triggering anti-tumor immunity [19].



Figure 3- In inflammation, cancer and autoimmunity, the role of controlling T cells, Th17 cells, and TLRs.

Dendritic cells

Dendritic cells (DCs) are a heterogeneous group of innate immune cells necessary for the presence and activation of antigen-born T cells. Nonetheless, DCs have been active in the activation of immune resistance posing the likelihood of dual immunity in cancer. This is also likely to contribute to the questionable definition of DC tumor penetration currently held [20].

Approximately 80% of exosomes extracted from lung cancer biopsies include the epidermal growth factor receptor (EGFR), which has the potential to produce sensitive DC and regulatory T-cells, contributing eventually to the suppression of tumor-specific CD8 + cells. Tumor-related exosome (TEX) contains mir-203a, which decreases the expression of TLR4 on DCs, resulting in lower development of downstream cytokines such as tumor necrosis factor (TNF)-α and IL-12, resulting in DC dysfunction and cell immunity [21]. Therefore, TEXs can disrupt the maturation and function of DCs. The administration of TEXs filled with ovalbumin in a murine delayed-type hypersensitivity (DTH). The experiment culminated in DTH responses being inhibited by inhibiting TGF-β1 DC maturation. This result demonstrates the roles of TEXs in tumor-specific immunosuppression, presumably by modulating the characteristics of DCs. TEXs mutually change the monocyte division into DCs and promote the preservation of immature monocyte status. Such cells spontaneously secrete TGF-β and prostaglandin E2-inhibiting cytokines that impede T-cell proliferation and anti-tumor characteristics [19].

Natural killer cell

Natural killer (NK) cells are identified in the immune cytokine network as a subset of cytotoxic innate lymphoid cells that provide essential features. In infectious non-self ligands of "distress" and TLR ligands, NK cell receptors are activated [22].

Lung cancer-associated tumor-associated exosome (TEX) contains miR-21 and miR-29a, each of which can bind to intracellular toll-like receptors (TLRs) on immune cells together with NKs, thereby activating a pro-metastatic inflammatory response due to NF-πB activation, thus ensuring metastasis and tumor development. For NKs, C-type lectin such as the NKG2D receptor functions as an activated receptor that induces cytotoxicity in cancer cells to decide their ligand. TEX originating from hypoxic tumor cells inhibit NK feature through turning in transforming the increased element (TGF)-β1 to NKs and because of this decreases NKG2D expression [23].

Vaccine therapy

Cancer vaccinations are biologically active antigenic preparations that preferably inform the immune system about emerging cancer. To be successful, a cancer vaccine may target a cancer cell-specific antigen, i.e., tumor-associated antigens (TAA), which are often elevated in cancer patients' circulation. Historically, vaccinations were (glyco) peptides, recombinant proteins, or whole cancer cell preparations (which culminated in inadequate replication); because antigenic peptides cause antigen processing cells (APCs) sub-optimally; Inactive pathogen form or multiple non-specific antibody stimulants [24]. APCs are used for cancer vaccinations,

which then travel to the closest contracting lymph node and cause T- and B-lymphocytes as a result. Specific T-cells can recognize and enhance tumor-specific effector cells that are domestic in the tumor microenvironment that houses the genuine antigens. Speculating that immune-centered therapies will be more effective if the tumor is initially damaged by cytotoxic chemotherapy and/or radiation or some other form of cell destruction, i.e., radiofrequency ablation/cryotherapy / oncolytic virus to improve immune system responsiveness to the antigen/epitope, is an operation. For medical trials treating people with NSCLC, many forms of cancer vaccinations have been tested [25].

Belagenpumatucel-L

Belagenpumatucel-L (Lucanix ®) (NovaRx Corporation, San Diego, California, USA) is an allogeneic tumor cell vaccine consisting of 4 irradiated human NSCLC cell lines SK-LU-1 (adenocarcinoma), NCI-H 460 (large cell carcinoma), NCI-H 520 and Rh2 squamous cell carcinoma transfected with an antisense assembly comprising transgenic plasmid as opposed to the TGF-β2 allele. That was currently evaluated in the phase III STOP trial (NCT00676507). While the STOP trial did not meet the major endpoint, particular subgroups had marked enhancement in survival [26].

TG4010

The TG4010 vaccine is a complete protein vaccine based entirely on a recombinant viral vector expressing as immunostimulants the total MUC1 and IL-2 antigen. The initial phase II randomized study involving 65 patients with stage III / V NSCLC showed that TG4010 (108 plaque-forming units administered subcutaneously for 6 weeks for every 3 weeks) in combination with chemotherapy (cisplatin/vinorelbine) (N=44) vs TG4010 monotherapy before chemotherapy was identified [27].

BLP25

BLP25 (Tecemotide ®) (also called L-BLP25 and Stimuvax) is a liposomal vaccine made up of immunoadjuvant monophosphoryl lipid A and three lipid components (cholesterol, dimyristoyl phosphatidylglycerol, and dipalmitoyl phosphatidylcholine). It harbors a 25 MUC1 TAA amino acid synthetic core peptide shown to have a solid T-cell immune response in both the models of transgenic murine lung cancer and in patients [26, 27].

Immune checkpoint regulator

A complex multifaceted mechanism occurs between T-cells known as initiation of adaptive immunity as well as APCs. A homeostatic balance between inhibitory signs as well as to quit under/ over-stimulation of T-cells stimulatory is necessary, might additionally lead to immune suppression sequelae or maybe autoimmunity, correspondingly. APCs may antigen internationally, custom it, along with particularizing the antigen on its surface in the perspective of Type II HLA that subsequently on the counter of T-cells engages the T-cell receptor. The co-stimulatory particles A 2d signal simplified through CD28 on T-cell surface binding of the area on APCs through CD86 (B7-2). T-cells are stimulated as a consequence of these unique associations and secrete cytokines (third signal) such as IL-2 inducing clonal proliferation of T-cells. To autoimmunity avoidance, cytotoxic T-lymphocyte antigen four (CTLA-4) controlled T-cell proliferation adversely that conveyed over the surface area of triggered T-cells. CTLA-4 is a part of immunoglobulin as well as additionally binds to B7-2 with a lot of higher affinity than CD28 also consequently as shown the T-cell reply is printed controlled. CTLA-4 is transmitted through the Tregs so that the effector T-cells can be inhibited. CTLA-4 laws arise in the early initiation stages of immune stimulation arising at the stage of the APC in the area of lymph nodes and unprinted T-cell activity [10, 11].

Nivolumab

Nivolumab (Bristol-Myers Squibb) and MK-3475 (Merck) are completely human antibodies that block PD-1 receptors on activated T cells. All obstruct the binding of PDL-1/2 with PD-1 on the triggered T-cells surface, moreover consequently boosting the activation of T-cells by taking out the PD-1 inhibitory signaling. Since PDL-1 is expressed only in selected tumor cells, it is expected that the adverse effect of the drug is less than ipilimumab (Table 1) [24].

Ipilimumab

Ipilimumab additionally referred to as also MDX-010 and MDX-101 is an antibody guided by CTLA-4 particle which is a human monoclonal. Ipilimumab blocks CTLA-4's interaction with the ligand B7-2 of its, leading to activation of T-cells, induction of cytotoxic cytokines, proliferation along with tumor suppression [24].

Table 1. The induction of Nivolumab.

Cancers	Single agent	Combination with Ipilimumab
Melanoma	BRAF V600 wild type unresectable or metastatic melanoma. Unresectable or metastatic, BRAF V600 mutation-positive melanoma and disease progression following ipilimumab and a BRAF inhibitor.	BRAF V600 wild type unresectable or metastatic melanoma
NSCLC	Metastatic NSCLC in patients with progression on or after platinum based chemotherapy.	Nivolumab
Renal cancer	Advanced renal cell carcinoma in patients who have received prior antiangiogenic therapy.	Nivolumab

CONCLUSION

Empirical evidence supports a pivotal role for the immune microenvironment in modulating tumor biology at the early stages of carcinogenesis. Current growing interest is therefore to define whether PMLs are indeed targetable by the various modalities of immunotherapy, an endeavor which has indirectly expanded our knowledge of the immune contexture in lung cancer. Future directions aimed at understanding the premalignant immune biology of various tumors promise to reveal unprecedented states of tumor plasticity, heterogeneity, and diversity of lymphoid and myeloid cell types in lesions, to harvest potential biomarkers for immune-based treatment of this fatal disease.

CONFLICT OF INTEREST

None declared.

ACKNOWLEDGMENTS

The authors thank the vice-chancellor Dr. A.P.J. Technical University, Lucknow, Uttar Pradesh, India, for his sustained encouragement, meticulous supervision, and valuable suggestions at all stages of completion of this manuscript. The authors are also thankful to Er. Mahesh Goel, Managing Director, Goel Institute of Pharmacy & Sciences, Lucknow, Uttar Pradesh, India for providing the library facilities for the compilation of the current review.

REFERENCES

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics. CA Cancer J Clin. 2014;64:9-29. doi: 10.12691/ajcp-6-2-5.
2. Birch R, Omura G, Greco FA and Perez C. Patterns of failure in combined chemotherapy and radiotherapy for limited small cell lung cancer: Southeastern Cancer Study Group experience. NCI Monogr. 1988;6:265-70.
3. Pesch B, Kendzia B, Gustavsson P, Jockel KH, Johnen G, Pohlabeln H, et al. Cigarette smoking and lung cancer–relative risk estimates for the major histological types from a pooled analysis of case–control studies. Int J Cancer. 2012;131:1210-19. doi: 10.1002/ijc.27339
4. Engels EA, Pfeiffer RM, Fraumeni JF, Kasiske BL, Israni AK, Snyder JJ, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306:1891-01. doi: 10.1001/jama.2011.1592
5. Swartz MA, Iida N, Roberts EW, Sangaletti S, Wong MH, Yull FE, et al. Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res. 2012;10:2473-80.
6. American Cancer Society. Cancer Treatment & Survivorship Facts & Figures 2019-2021. Atlanta: American Cancer Society; 2019.
7. Ogino S, Galon J, Fuchs C and Dranoff G. Cancer immunology - analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol. 2011;8: 711–19.
8. Pao W and Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncology. 2011;12:175-180.
9. Wan Y and Flavell R. How diverse–CD4 effector T cells and their functions. J Mol Cell Biol. 2009;1:20-36.
10. Maggi E. The TH1/TH2 paradigm in allergy. Immunotechnology. 1998;3:233-44.
11. Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, Nakakubo Y, et al. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer. 2006;94:275-80. doi: 10.1038/sj.bjc.6602934.
12. Brown D. Cytolytic CD4 cells: Direct mediators in infectious disease and malignancy. Cellular Immunology. 2010;262:89-95.

13. Keir ME, Butte MJ, Freeman GJ and Sharpe A. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677-04.

14. Mahnke K, Schonfeld K, Fondel S, Ring S, Karakhanova S, Wiedemeyer K, et al. Depletion of CD4+ CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions *in-vivo* and *in-vitro*. International Joural of Cancer. 2007;120:2723-33.

15. Petersen RP, Campa MJ, Sperlazza J, Conlon D, Joshi MB, Harpole Jr DH, et al. Tumor infiltrating Foxp3 regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer. 2006;107:2866-72.

16. Jeon H and Jen J. TGF-² Signaling and the Role of Inhibitory Smads in Non-small Cell Lung Cancer. J Thorac Oncol. 2010;5:417-19.

17. Roberts AB, Wakefield LM. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA. 2003;100:8621-23. doi: 10.1073/pnas.1633291100.

18. Tao H, Mimura Y, Aoe K, Kobayashi S, Yamamoto H, Matsuda E, et al. Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells. Lung Cancer. 2012;75:95-01.

19. Chen W, Jiang J, Xia W and Huang J. Tumor-related exosomes contribute to tumor-promoting microenvironment: an immunological perspective. J Immunol Res. 2016;2016:2747402. doi: 10.1155/2016/2747402.

20. Dai F, Liu L, Che G, Yu N, Pu Q, Zhang S, et al. The number and microlocalization of tumor-associated immune cells are associated with patient's survival time in non-small cell lung cancer. BMC Cancer. 2010;10:220. doi: 10.1186/1471-2407-10-220.

21. Zhou M, Chen J, Zhou L, Chen W, Ding G, Cao L. Pancreatic cancer derived exosomes regulate the expression of TLR4 in dendritic cells via miR-203. Cell Immunol. 2014;292:65-69.

22. Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol. 2012;12:239-52. doi: 10.1038/nri3174.

23. Malmberg K, Carlsten M, Bjorklund A, Sohlberg E, Bryceson Y et al. Natural killer cell-mediated immunosurveillance of human cancer. Semin Immunol. 2017;31:20-29. doi: 10.1016/j.smim.2017.08.002.

24. Mostafa A, Morris D. Immunotherapy for lung cancer: has it finally arrived? Front Oncol. 2014; 4:288. doi: 10.3389/fonc.2014.00288.

25. Drake CG, Lipson EJ, Brahmer J. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol. 2014;11: 24-37.

26. Nemunaitis J, Murray N. Immune-modulating vaccines in non-small cell lung cancer. J Thorac Oncol. 2006;1:756-61.

27. Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Soulieres D, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non–small-cell lung cancer. J Clin Oncol. 2005;23: 6674-81.